MGNX stock forecast, quote, news & analysis
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer... Show more
Why MacroGenics (MGNX) Stock Is Down -14% in the Last 30 Days
Key Takeaways
- MacroGenics (MGNX) shares declined roughly 14% over the trailing 30 days, falling from about $4.14 to near $3.55.
- The pullback follows a strong 2026 advance and occurred despite positive company milestones, including first-patient dosing of the MGC030 ADC program.
- Over the last quarter, the stock is down approximately 18%, retreating from a mid-July peak near $4.49.
- MacroGenics has strengthened its financial position, with pro forma cash of roughly $327 million funding operations into 2028.
- Near-term catalysts include ESMO 2026 data for MGC026 and lorigerlimab and preliminary MGC028 results later in 2026.
MacroGenics (MGNX) Company Overview and Market Position
MacroGenics, Inc. is a clinical-stage biopharmaceutical company headquartered in Rockville, Maryland, that develops innovative antibody-based therapeutics for cancer. The company builds its pipeline from a proprietary suite of next-generation antibody platforms, including its DART and TRIDENT bispecific technologies and its antibody-drug conjugate (ADC) capabilities.
Its clinical-stage assets include three ADCs using a topoisomerase I inhibitor-based linker-payload — MGC026 (targeting B7-H3), MGC028 (targeting ADAM9), and MGC030 — along with lorigerlimab, a PD-1 × CTLA-4 bispecific DART molecule. MacroGenics also derives value from collaborations and royalty streams with partners such as Gilead Sciences (GILD), Sanofi (SNY), and Incyte. Investors follow the stock primarily for its oncology pipeline catalysts and milestone-driven revenue model.
MacroGenics (MGNX) Stock Price Performance: Last 30 Days vs. Quarter
Over the past 30 days, MGNX has moved lower by approximately 14%, declining from a closing level of about $4.14 in mid-September to roughly $3.55. The decline has been characterized by choppy, low-volume trading and a series of step-downs rather than a single sharp catalyst-driven move.
The broader quarterly picture shows a similar but more pronounced downward trend. From a mid-July closing level near $4.32 — and an intraday peak around $4.49 — the stock has retreated roughly 18% to current levels. This marks a reversal from the strong gains recorded earlier in 2026, when the shares rallied significantly from their prior-year lows before consolidating and giving back ground in the late summer and early fall.
What Drove MGNX Stock Price in the Last 30 Days
The 30-day decline appears driven less by company-specific bad news and more by a challenging backdrop for small-cap biotechnology. Elevated Treasury yields — with the 10-year yield trading near 5.3% — have pressured risk appetite across the sector, and thin trading volume in a roughly $237 million market-cap stock has amplified daily swings.
Positive developments during the period were not enough to offset the selling. On October 15, MacroGenics announced the first patient had been dosed in a Phase 1 study of MGC030, a first-in-class ADC directed against an undisclosed target in advanced solid tumors. Separately, the company had earlier confirmed a $10 million milestone payment from Gilead Sciences after Gilead exercised an option on a preclinical bispecific program. Despite these advances, profit-taking after the year's rally and broad sector rotation kept the stock under pressure.
What Drove MGNX Stock Performance Over the Last Quarter
The last quarter was defined by a strategic transformation alongside a cooling of investor enthusiasm. MacroGenics completed the sale of its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million, transitioning to a fully outsourced model with a leaner workforce of about 140 employees focused on drug discovery and development.
On August 13, the company reported second-quarter 2026 revenue of $32.8 million, up from $6.9 million a year earlier, while its net loss widened to $69.6 million. The results reflected a mix of partnership and milestone revenue against higher operating costs. The balance sheet, however, improved materially: pro forma cash of about $327 million extends the company's runway into 2028. Additional non-dilutive capital included an expanded ZYNYZ royalty purchase agreement with Sagard Healthcare Partners and a $24.5 million Sanofi milestone tied to TZIELD approval.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant strategies appear in this section. These bots vary widely in strategy, timeframe, and performance metrics, allowing users to explore approaches ranging from short-term signals to longer-horizon models. The page provides a useful way to see how quantitative systems are positioning across the market. Investors interested in automated, rules-based analysis can explore the available bots to find strategies aligned with their own research.
MGNX Stock Forecast Drivers: What Investors Should Watch Next
Several near-term catalysts could shape MGNX's trajectory. The most immediate is the ESMO 2026 Congress in Madrid (October 23–27), where the company plans to present data for MGC026 and lorigerlimab. Investors will also monitor preliminary MGC028 data expected in late 2026 and the continued progression of the MGC030 Phase 1 trial.
Beyond clinical readouts, watch for updates on partnership milestones, the pace of cash burn against the company's runway, and any further collaboration activity. On the macro side, interest-rate dynamics and risk appetite for small-cap biotech remain important influences on valuation. As with all clinical-stage developers, trial results are inherently binary, and the shares can remain volatile around data disclosures.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for MGNX turns positive, indicating new upward trend
MGNX saw its Momentum Indicator move above the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 78 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 67 cases where MGNX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for MGNX just turned positive on October 21, 2026. Looking at past instances where MGNX's MACD turned positive, the stock continued to rise in 43 of 52 cases over the following month. The odds of a continued upward trend are 83%.
Following a +4.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 229 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
MGNX moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MGNX crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for MGNX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.393) is normal, around the industry mean (2.973). P/E Ratio (-16.500) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the discovery and development of monoclonal antibody-based therapeutics
Industry Biotechnology